Allogene Therapeutics, a clinical-stage biotech working on cancer-fighting T-cell therapies, recruited seasoned startup lawyer Earl Douglas as general counsel.

Douglas has a rich background in the biotech startup world. He was most recently executive vice president and general counsel of Applied Molecular Transport, a biopharmaceutical company developing treatments for severe autoimmune, metabolic and inflammatory diseases.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]